Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
5 Best High Earnings Yield Picks to Grow Your Wealth
09:02am, Tuesday, 07'th Feb 2023
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
10:50pm, Monday, 06'th Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed at $15.87 in the latest trading session, marking a -1.43% move from the prior day.
The 7 Best Growth Stocks to Buy for February 2023
05:14pm, Monday, 06'th Feb 2023
The search for growth stocks, or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings bac
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
02:00pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
10:32am, Friday, 03'rd Feb 2023
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Catalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement Concerns
01:54am, Wednesday, 01'st Feb 2023
Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
11:20am, Tuesday, 31'st Jan 2023 Zacks Investment Research
Style Box ETF report for JPSE
Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know
10:50pm, Monday, 30'th Jan 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.72, moving +1.29% from the previous trading session.
Catalyst Pharmaceuticals: The Firdapse Complexity Does Not End
06:21pm, Monday, 30'th Jan 2023
Catalyst Pharmaceuticals, Inc. has been hit with an ANDA notice from Teva Pharmaceutical Industries Limited. Firdapse, at the heart of the ANDA, has had problems before.
3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence
12:26pm, Monday, 30'th Jan 2023 Zacks Investment Research
World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence
09:02am, Monday, 30'th Jan 2023
World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
02:56pm, Friday, 27'th Jan 2023
Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
Zacks.com featured highlights include Lamb Weston, Pinduoduo and Catalyst Pharmaceuticals
12:14pm, Friday, 27'th Jan 2023 Zacks Investment Research
Lamb Weston, Pinduoduo and Catalyst Pharmaceuticals are part of the Zacks Screen of the Week article.
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
02:22pm, Thursday, 26'th Jan 2023 The Motley Fool
Things aren't as bad as they might seem.
3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio
11:30am, Thursday, 26'th Jan 2023 Zacks Investment Research
Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.
